Earnings ·
Cytosorbents Corporation filed an 8-K to furnish its Q2 2026 earnings investor presentation
CTSOCytosorbents Corp
Cytosorbents Corporation filed an 8-K to furnish its Q2 2026 earnings investor presentation. The company reported Q2 2026 revenue of $9.6 million, with gross margins improving to 73%. Operating loss narrowed by 27% to $2.6 million, and adjusted EBITDA improved by 38% to a loss of $1.6 million. Management expects operating cash flow breakeven in the second half of 2026. The presentation detailed regulatory setbacks for DrugSorb-ATR, noting an FDA denial of its De Novo application due to missing primary efficacy endpoints, though the agency indicated a new submission is possible with additional data. Cytosorbents operates in the medical device industry, developing blood purification technologies.